CHM.AX is trading up 8% at $0.07, continuing its recovery as investors remain optimistic following strong clinical trial data.
- Sentiment remains supported by late April results from the CORE-NK Phase 1B trial, which demonstrated a 60% CR/CRi rate.
- The stock is rebounding from recent volatility, though there have been no fresh announcements from the company today.
- Chimeric Therapeutics remains a high-risk micro-cap biotech, with current price action driven by momentum from previous clinical success.